Introduction to Hemogenyx

Hemogenyx Pharmaceuticals is a pre-clinical stage bio-pharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease. Despite their small size and valuation they are working with several large global Pharmaceutical companies including Eli Lilly, Johnson & Johnson, Orgenesis and others.

Subsequent posts will highlight the current pipeline of therapeutics which are cutting edge and if successful will save many lives and improve the quality of life for many patients.

Elephant in the room

Its worth addressing the elephant in the room, the Share Price and mCap, at time of writing the share price was 2.075p with an mCap of just £20m. Subsequent posts will hopefully clarify what I believe the company is worth however, its relevant to explain how we got to the current price.

18th November 2020 – Hemogenyx announced Financing Facility of upto £60million with an initial tranche of £12million to be drawn down on 11th February 2021 announced on 3rd February 2021. The structure of this loan was such that the issuer of the loan, Mint Capital, was issued Convertible Loan Notes which could at any point after the loan was drawn be converted into shares in Hemogenyx. The terms were such that on conversion of the CLNs into shares the price used to decide how many shares issued would be the lower of the closing bid price for the previous 3 trading sessions minus 10% discount. This in essence guaranteed that Mint would be able to forward sell any number of shares up to 30% of the company and be assured that at any point they could convert CLNs for a price they were able to accurately predict.

As a loan facility the ability to access £60million gave Hemogenyx the ability to approach global pharma and negotiate with a strong financial position. Had the market reacted positively to this facility and rewarded Hemogenyx with a strong Share Price then the CLN facility would have been a welcome cash injection with minimal dilution. This was not the case and what came next was an overall negative reaction with the SP falling steadily and investors either turning away from Hemogenyx or becoming bearish and either taking the opportunity to trade down, de-ramping and short selling the company. Once the CLN conversions begun Mint started steadily and slowly converting and selling shares, but always taking advantage of any spikes and locking in lower prices with each conversion.

Whilst this was going on sentiment was strong that Global Co who have been working with Hemogenyx for several years on their CDX candidate (details to follow) would buy the CDX antibody from Hemogenyx for a substantial upfront cash payment late 2020 or early 2021. As such many investors had become laser focused on this key event as being the reason for continued investment, the turning point in the company and the point at which the Mint CLNs would be terminated. However on 14th April 2021 the CDX Option Update announced that Global Co did not wish to licence the CDX IP from Hemogenyx at that point. This RNS failed miserably to convey that Global Co would continue to work with Hemogenyx through clinical trials and were still likely to take CDX once it was proven. As a result of this perfect storm of disappointed investors plus the CLNs the share price collapsed pre-open.

From this point Mint Capital began dumping of shares with haste keen to exit the lending facility as quickly as possible with little regard for the damage done to the company. The resulting chaos proceeded until 18th May 2021 when Hemogenyx were able to negotiate with Mint Capital to repay and cancel the outstanding CLN facility in full. This was not without further pain as although £1.6million worth of CLNs were repaid in cash and cancelled with immediate effect £6.5million worth of CLNs were sold to placees arranged by Peterhouse Capital and immediately converted to shares in Hemogenyx at an issue price of 1.5p resulting in an additional 433million shares.

Within the first few days of the CLN cancellation it became apparent that many of the placees had taken advantage of the significant discount and flipped immediately. All these events have led to a situation where in a very short space of time the market has had to absorb millions of shares at ever falling share prices with long term investors constantly taking the brunt of any pain. The good news is the pain is over, CLNs are gone, the arrangement with Mint has been terminated and as subsequent posts will highlight the future is looking bright for Hemogenyx investors.

So what now?

As of today Hemogenyx has a Market Cap of £20mil with 980million shares.

To read the various forums you would be excused for thinking the company is a shell with nothing to offer and just a scam. But when you actually start to dig deeper its clear that big names, seriously big names, the likes of Eli Lilly and J&J are taking this company seriously. Its not a scam, its not “Fake news” the science is real, the achievements are real.

It was trading with an mCap of £50mil last year and since then every pipeline has continued to advance towards clinical proof of concept. They have the addition of CBR which is being called a “Stealth project”. They have up to £10mil cash in the bank to fund the clinical trials. I love a bargain and the deeper you dive the bigger an opportunity this appears to be. Without the impending threat of further Mint conversions or additional dilution in the immediate future this share should do extremely well.

Hemogenyx Investor Presentation

A new presentation is available here dated 2nd July 2021.

Looks like the company is starting to answer investor calls for better Investor engagement, the presentation itself should also perk the ears of the pharma community. Some key takeaways:

  • Explicitly names some massive names as collaborators including Ely Lilly, Janssen Pharmaceuticals, Orgenesis, Penn, Center for Cellular Immunotherapies and Global Co.
  • 6 Products in the pipeline compared with 2 previously despite the mCap substantially lower.
  • De-risked due to humanised animal studies and expect to be ready for clinical trials upon completion of IND studies.
  • Cash on hand, all indications they will be into clinical trials before any additional funding is required, and as previously stated the intention is to partner or licence products once clinical proof is achieved.

As far as small cap pharma goes Hemogenyx is the one with the biggest potential, the board of advisers and scientists are world leading and the products they are developing whilst life saving are also potentially worth billions. Due to their humanised mice models its expected that most if not all products will perform well in clinical trials which are due to begin soon. Its often the case that a small company like this would be unlisted and available only to angel investors, those that are listed would expect to be worth 100-200mil mCap. Its the unfortunate series of events that have led the company to today’s damaged SP which is bad news for the company if they ever wish to raise capital in the future but an absolute gift for investors who happen to come across the opportunity.

This should not be considered financial advice and the author is a shareholder in this company.

Half-year Report

Have not updated for a while but off the back of the Half Year report an update was due. The report was significant and gives a good insight into the operations of Hemogenyx, I have extracted what I believe to be some key points:


The report goes into detail about the CLN facility which caused a technical crash of the SP, it also makes clear the facility and attached risk is now gone. The company holds approx £10m cash at hand with an approximate burn down of £3m per year and have confirmed they believe they have enough capital for at least 12 months.

CDX Antibodies

Detailed negotiations are ongoing with GlobalCo as to the exact terms of the licencing and Global Co’s involvement in progressing CDX towards clinical trials. The report makes a point to highlight work with Global Co continued at pace AFTER the initial development work completed. What is significant is that both parties are currently working “naked” as the existing development contract has expired, either side could walk away leaving the other high and dry having wasted considerable time and money. This co-operation and continuation of effort whilst negotiations take place is a demonstration of both sides commitment to get the deal done and a very positive indication.


This is a significant update: “the Company has engaged a contract development and manufacturing organisation that will manufacture DNA plasmids and viral vectors for the production of HEMO-CAR-T for clinical trials.” There are 3 manufacturers required, what is outstanding is an organisation to produce the CAR if my understanding is correct. This is a necessary step in taking CAR-T to clinical trials and a strong and positive indicator of progress. Is it likely Hemogenyx would have secured 2 of the 3 suppliers to produce HEMO-CAR-T if they were not imminently prepared to file IND application and begin clinical trials?

The half year report also goes to pains to call out the significance that despite this advanced stage of HEMO-CAR-T and the Master Translational Research Services Agreement with the University of Penn the company retains 100% of the IP associated with this product. As highlighted elsewhere on this site CAR-T is an explosive and valuable sector worth billions, proof of clinical concept of HEMO-CAR-T would be game changing to the company.


The company has acknowledged a failure to update the market regularly and committed to update more as time progresses. This is due to a gradual consistent development rather than specific key milestones, however taken as a whole CBR has hit key milestones. First they have identified 2 key product candidates although more available, one for Covid-19 and one for an undisclosed type of cancer. In Vitro experiments have been successful and testing continues. Given the ability of Covid-19 to beat vaccines and mutate it is possible CBR may actually have a role at some point in the future. Early days but certainly a promising pipeline to watch.

Autoimmune Diseases

As reported in June 2020, the Company entered into an agreement with Eli Lilly and Company (“Lilly”) …. In recent months this work has significantly accelerated. Lilly and the Company are now progressing with the initial selection of potential drug candidates. This is a significant progression from our last update where we knew nothing, the next stages after selection of candidates will either be further testing or licencing, either indicates strong progress.


The unique properties of the patented monoclonal antibodies were the primary driver in bringing GlobalCo to enter into an agreement to develop CDX. The Company has made further patent applications in relation both to HEMO-CAR-T and to the CDX bi-specific antibodies, the latter entailing a joint application with GlobalCo. – The patents secured by hemogenyx provide key connectors to bind to multiple cells in the body including cancer cells and Bone Marrow stem cells. With a limited number of targets and patents granted the patents granted give Hemogenyx a massive presence in the Bone Marrow Transplant market and AML treatments. I will do a more detailed article on the Patents and the significance when time permits, suffice to say in my opinion they are worth as they stand many multiples of the current companies mCap even without CDX or CAR-T.


The company has taken on more staff, more scientists and are moving to a new larger premises in the near future, all key signs of growth.


As a shareholder in this company having read all previous updates I read the recent Half Year report with the expectation of nothing new. I expected no surprises or NEW information, I was plesently surprised. The Report does several things, it reassures us that the company is financially secure and well funded, dilution is unlikely and risk is mitigated, in terms of value the Patents secured + assets easily underpin the mCap. There are 4 key active pipelines, Lupus is the big surprise appearing to be close to a key milestone of selecting a candidate for progression. CAR-T is also primed for clinical trials requiring only IND application and CAR manufacturer, CBR is progressing nicely and will hopefully update soon. CDX is the primary focus of all investors however and whats clear is both Hemogenyx and Global Co are operating as if the licencing agreement is a done deal. The failure to halt progress pending a successful agreement shows both parties are committed to getting it done. At an mCap of 19mil the upside here is massive, there is always risk and the report highlights these risks.

None of this article should be taken as investment advice, do your own research, what is presented here is MY opinion only with no guarantee of accuracy. Please read the official RNS which can be found HERE.

CDX Licence Agreement

Hemogenyx Pharmaceuticals #HEMO, announces that it has signed a licence agreement (the “Agreement”) with Eli Lilly and Company (“Lilly”). Under this Agreement, Lilly grants the Company an exclusive worldwide licence to certain intellectual property developed by Lilly (“IP”) related to a CDX bispecific antibody for all uses, including the treatment of acute myeloid leukemia (“AML”) and other blood cancers.

A lead CDX antibody candidate has been successfully created and the Company is initiating investigational new drug (“IND”)-enabling studies that include manufacturing of the antibody for animal toxicology studies and subsequent clinical trials. The work done to date fully validates the Company’s original expectations and shows wider potential applications for CDX than originally envisaged. It is now being developed for conditioning for bone marrow transplantation and also for the treatment of several blood cancers, as further described below in the section headed ‘About CDX’ below.

Confirmation at long last that Global Co is Eli Lilly, confirmation that CDX works against a whole range of targets and not just AML. With a small upfront payment but Eli expecting substantial royalties and payments down the line instead just demonstrates they know what Hemo have is worth the big bucks. In my opinion today’s announcement unlocks Hemogenyx from the bureaucracy of big business so they can get to clinical trials faster but its clear Eli Lilly are behind this project. Zero risk for Eli at this point with the ability to just buy Hemo when CDX is proven in clinical trials.

Interview with Zak Mir

Link to interview
Zak: Hello and welcome to Vox Markets. I'm joined by Dr. Vladislav Sandler, who's CEO and co-founder of Hemogenyx.

Vlad: Hi, Zack. Thank you for inviting me. I'm good today. And as you correctly pointed out, I co-founder and CEO of Hemogenyx Pharmaceuticals.

Zak: It's just good to underline the fact that this is your baby, your idea and your concept. So what was interesting this week is that you actually came out with an announcement, which could be probably, from my perspective, at least a world beating one, a really welcome one. I would describe it as a sort of universal virus killer. And so far, the market doesn't seem to have noticed or understood that what you're actually sitting on. How would you describe the latest CPR update?

Vlad: Well, we worked on this platform for quite a while, and this is a transformational platform that we discovered transformational for both the company and for potentially the patients. And I would say that it takes probably time for the market to digest what is happening. But in short, we basically worked on this for quite a while and we came to we came up with the solution of most viral infections using this platform.

Zak: Really this smallcap or micro-cap company that you are at the moment. If you could monetize this, you would not be a small cap microcap company anymore. What are the barriers to monetization, to development of this product?

Vlad: Right. So we filed a provisional patent application that covers this platform and that was a lot of work because the platform itself is quite big and we have to pay very serious attention of how to describe it and how to protect the intellectual property behind this development. And the next step would be to demonstrate in-vivo in a model with a real infectious virus. And we're working with a third party that can give us access to so called BSL three facility that the facility where we can work with real infectious viruses to demonstrate that this approach works in the real world. So that's the first step that we're going to take. And then after after we establish this, it works in vivo. We will start talking to a number of big companies, trying to get them on board to support this, to support this development and to take it to take it to the clinic, basically.

Zak: But I mean, clearly you're satisfied that it works before obviously having to demonstrate to the outside world that it works.

Vlad: Yes. So we did a lot of work. We worked on this for almost three years, even before COVID. And we you know, we had to overcome a lot of different obstacles because it's such a new thing. We didn't know where to go and how to do it. We had an original idea, but now we know that it does work. So we demonstrated that it does work in vitro and we know how to modify this chimeric receptor SEEBER To adapt it to different viruses and then potentially to adapt it to even attack malignant or cancer cells.

Zak: All right. So obviously it's very early stage, but can you what's the addressable market as people like to talk about?

Vlad: We didn't even try to figure it out simply because it will depend on what's on the applications. So for example, if we think about COVID, then it's it's clear that there are hundreds of thousands of immunocompromised and older people who get the virus and whoever serious that causes a very serious condition in this in this in these patients. And they need some sort of treatment beyond vaccines and beyond the antibodies that exist. So we think that the market is large and it doesn't seem like, for example, COVID will will go away forever. We tried also this for other types of types of viruses. In fact, we started with measles and people would probably wonder why measles. But the reality is that measles kills more than 100,000 people in the developed world per year. So there is market there, too. And obviously there are other applications for this platform. For example, such applications as biodefense and we don't know what's the market there.

Zak: I think anybody following the company over the last few years will know that you've got a lot of retail investors interest in the stock. They've been excited with various announcements. You made the announcement, obviously, then this announcement. Do you think this is the most important announcement you've made to date?

Vlad: I think it is the most important announcement because it puts our company on the map as a company that has something absolutely unique. So this platform is truly unique and it will allow the company to target different indications, different diseases, different viruses. And this is this is something that most companies are looking for. If you look at our product candidates, they are great and they are unique in their own kind of universe because they target a specific disease, specific condition, and they do it better probably than most other approaches. But CPR is a is a platform technology that allows us to develop multiple different product candidates and partner with multiple different with multiple companies.

Zak: And is there any indication at the moment on how long it would take to monetize that or you don't you don't know yet. Is it too early?

Vlad: We we don't know how long it's going to take. So it will depend on how fast we will get in proof of principle. And then if we get it right, if we get if we demonstrate that it works in vivo, then it may go fast.

Zak: And finally, this this does sound like the sort of thing or would you think this is the sort of thing which would win a Nobel Prize? Is it that good?

Vlad: I don't think about any prizes. I think about to be honest, I think about patients and people who are suffering and dying. That's the most important thing. We have an advisor, you know, Mike Shepherd, who worked all his life on Herceptin, you know, developing a drug for breast cancer. He didn't think about any prizes and no one could even predict that he would get a prize. But after he cured I mean, after his drug, he was tens of thousands, maybe hundreds of thousands of women. Yeah, he got a prize. But I mean, what's the value of that prize? I mean, it's just a diploma. And if you if your box basically and his name is now written in history, but it would have been written in history anyway because he saved so many people.

Zak: Let us see him again. Thank you very much, indeed.

Vlad: Thank you.

Speaker1: Nothing in this podcast is intended as investment advice, and the people in this podcast may hold positions in the stocks they talk about. Do not buy anything based solely on a tip or recommendation. Please do your own research.

Interview with Total Market Solutions

Link to interview

Sarah: You're listening to a Total Market Solutions podcast. Hemogenyx Pharmaceuticals has told investors that it has achieved proof of concept for its chimeric bait receptor platform technology. To find out what that means for the company, I'm joined by co founder and chief executive Dr. Vladislav Sandler. Thank you very much indeed for joining me. Vlad, so this development, is it fair to call it a virus killer technology at its most basic level?

Vlad: Hi, Sarah. Thank you for inviting me again. In some sense, yes. So I would like to give you some historic background. Sometime in the mid 2019, we came with the idea of creating a platform, creating the method of fighting emerging viruses. And at that time, the idea was basically to figure out what we would do if a new virus emerges. We obviously did not know about it at that time. We concentrated on measles virus and measles, despite the fact that the vaccine exists since I think 1963 still kills about 100,000 people every year. So we went and we had this idea of instead of targeting the virus, rather to use the propensity of the virus to latch on a specific type of cell or a specific part of the cell and use that part of the cell as a bait. So instead of trying to kill the virus, we wanted to attract the virus to basically trap. And when the virus gets into that trap, we would kill it or do something about it. So that was the original idea and we concentrated on measles. However, about a year later, we discovered that we are in the midst of a pandemic, of COVID 19 pandemic, and we switched to the virus that causes COVID 19, which is SARS-CoV-2. And we try to design, try to develop this trap for COVID 19 because in virus. So in some sense you are right. So we created a platform that can be used to make different traps for different types of types of viruses. And you can call it virus killer. Yes.

Sarah: So it's taken, what, from conception to proof of concept, it's taken about three years. So I'm just wondering what next for the CBA platform technology and what partnerships you'll need to integrate to take it to the next step.

Vlad: Yeah, you're absolutely right. It took about three years, a little bit less than three years to actually go from a pure idea of creating a trap for a virus to something that actually works. So we we had to overcome enormous amount of difficulties because one thing is to claim something as an idea. And the other one the other thing is to reduce this claim, to reduce this idea, to practice. That's the foundation. That's the essence of something that is patentable. So we not only have to show how it works, but we show the idea. But we'll also have to demonstrate that this idea is practical so that it works. So it took almost three years. We demonstrated this in vitro for SARS-CoV-2, and we demonstrated that the approach is not sensitive to mutations, and it works for all variants of COVID 19 that we tried. And there is no theoretical reason why it wouldn't work for five or ten or 50 other variants of the same virus, simply because we design the trap as if it's a door through which the virus comes and goes inside the cell. And as long as the door remains the same, it doesn't matter if the virus is spread thin or short. Right? It's the same door through which the virus goes in, gets trapped and killed.

Vlad: So in a sense, it's a universal approach that can be used not only for COVID 19, but also for all kinds of different viruses, I'm afraid to say, for all viruses, because we don't know what's coming and what exists actually out there. But based on what we see, I would be able to say for most viruses, for most known viruses. So the next step, obviously, to show that what we created works in vivo and it means that we would have to demonstrate that, for example, with COVID 19 virus, that our approach works with the real infectious replicating virus that can potentially infect people and even kill people. Demonstrate that this approach works in vivo, and then we will probably try to partner with other companies or governments to push this into clinical trials for certain populations of patients. In parallel with that, in this way, developing, we are expanding this platform, trying to see if this platform can generate treatments for other types of viruses. And as we discovered recently, it can be adapted for attracting and trapping malignant cells or cancer cells. And that opens a totally new area of application of severe.

Sarah: Did you say governments then, Vlad? The development partner could include governments. That's the highest level of administration in the land. Is that what you said?

Vlad: Yes, we are trying to. Talk to. You can call them governments. Yes, because it's absolutely clear now that emergent viral infections are as probably as dangerous as I'm afraid to say it's nuclear weapons, because it's absolutely clear that a developed country can be brought to its knees by bug that kills .01 percent of the population. It basically stops economy, disrupts everything. You don't even need to kill 1% of people. It's enough to kill 0.1% of people. And it creates enormous fear and people stop functioning. And so that's why governments and very large institutions that are designed and created to take care of stability in a country must be interested in something that can prevent such a horrible event.

Sarah: Yeah, I totally agree. Well, hopefully those conversations are already underway now. You mentioned patents a couple of minutes ago. Is this chimeric bait receptor? Is it well protected? Is it well patented so that no one else can create something similar and overtake you?

Vlad: Well, right. So we filed the provisional patent application, a very large we call it like a seminal patent application that protects different basically protects CBR as a platform and different types of applications of this platform for both viral infections and cancer. So it's a very large patent application. I'm not going to tell you how many claims and what are these claims, because it's going to be published probably in about one and a half years when we go through the initial 12 months of provisional patent application period, and then we will switch it into international application. And only after that in about 18 months since the original application is going to get published and then the whole world will see what it is all about. So by that time, we hope to move forward and basically aggressively and add a lot of data and a lot of new ideas and hopefully come closer to proof of concept in people, mainly come closer to clinical trials or even be in clinical trials and definitely have some, some products.

Sarah: You've been very, very clear in previous interviews that you like to keep things and you like to take a product, a treatment, an idea from conception to hopefully commercialization. Are you going to be as possessive with the CVR platform technology as well, or would you be prepared to sell it to Big Pharma if the right price was offered?

Vlad: We're not thinking about selling it because there are different applications of this platform. And when you say that I was possessive. So you have to keep in mind that we have two major product candidates. One is key, and the other one is a bispecific antibody. Both are for three for the treatment of acute myeloid leukemia and condition in bone marrow transplants. So these two product candidates are exceptionally good. I'm not afraid to say this because the more we work, the more we move forward, the more I'm convinced that they are really, really good product candidates. But they are not platform. They are single product candidates. So you cannot derive a lot from them. You can maybe expand the use of the CAR-T or BISPECIFIC antibody for maybe additional indications, but these are not platform technologies. They cannot serve as a point from where you can go into different directions basically and derive for the product candidates. So in the case of these product candidates, yes, I was possessive because the real value. Can be extracted only when both of these product candidates are in clinical trials and there is a clinical data that proves that they are really work and really save someone, someone's life to sell it before that. It doesn't it doesn't give the company or its investors the real return on investment.

Sarah: So.

Vlad: So in the case in the case of CPR, we have a platform that can be used to generate multiple product candidates. And obviously we cannot handle ourselves. All aspects of this technology. So most likely we will try and most likely we will find people or institutions or governments that will be interested to take over, to partner with and take away a part of that platform for a specific indication or a specific direction.

Sarah: Understood I wasn't being rude when I was saying possessive. It's wholly understandable. So in terms of the other homogeneous initiatives, how are they progressing and and do you have the funds to continue to progress them?

Vlad: Right. So our frontrunner is khaki for the treatment of acute myeloid leukemia and conditioning of bone marrow transplants. So we are basically in the middle of manufacturing of necessary components for CAR-T. And we announced sometime ago that we partnered with Gucci Advanced Cell Technology. That's a Chinese company that already manufactured plasmids or DNA to make the virus. They're in the middle of manufacturing the virus. And the final step, manufacturing of car key. Actual car key is going to be done by human genetics pharmaceuticals in its new facility that is being finished. And I don't want to say when we're going to move there, but it's a matter of the completion of this facility is a matter of days or weeks, basically.

Sarah: So in terms of this facility, though, Vlad, how is it going to benefit you?

Vlad: So by building this facility and acquiring expertise and manufacturing of actual car t cells for clinical trials, first of all, we save a lot of money. Let's start there. We save probably at least two and a half million just by doing this. And that is after the expense of building the facility and purchasing of all necessary equipment, hiring people and so on and so on. So after all of this, we will probably save about two and a half million. In addition to that, we will have experiences of manufacturing cell therapies and looking at CPR. And CPR is, at least partially is a cell therapy platform. We will have an opportunity to go and push it forward much, much faster, because we will have all infrastructure in place and we will have knowledge and ability to manufacture cells. For human use. So it gives us it basically expands the experience and ability of our company to move forward faster and more aggressive.

Sarah: And it seems as though 2022 is going to be a year without distraction. There were lots of distractions to the core business last year. So 2022, how confident are you that it will be the company making year that you were hoping last year would be?

Vlad: Um. Well, last year was a company making year too, because we advanced once tremendously. It's it's a process. It's not like we decided to do something today, and in a couple of weeks, voila, we are there. No, it's a constant. It's a it's a tedious process. We go step by step, overcoming different obstacles, learning new skills. And ultimately we will go into clinical trials with our source product, candidate CAR-T, and then hopefully with others. So I think I think we are on the right track and we will get to where we are going. And I firmly believe that the share price and this is very sensitive for many people who invested in our company will follow our scientific and engineering and manufacturing progress.

Sarah: Well, if today is anything to go by, Vlad, today is Monday, the start of the week, and the share price is up 21%. So that's not a bad start to the week at all. And with that, we shall conclude our catch up with gratitude and thanks. Thank you so much. Vladislav Sandler, Co-Founder and chief executive. Thank you very much indeed.

Vlad: Thank you.